Author:
Xing Yingying,Bao Weiwei,Fan Xiaobo,Liu Kunmei,Li Xiaokang,Xi Tao
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Biochemistry, medical,Cell Biology,Clinical Biochemistry,Pharmaceutical Science,Pharmacology
Reference25 articles.
1. Wheate NJ, Walker S, Craig GE, Oun R (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39:8113–8127
2. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM (1979) Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63:1527–1531
3. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC (1997) Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57:850–856
4. Montana AM, Batalla C (2009) The rational design of anticancer platinum complexes: the importance of the structure–activity relationship. Curr Med Chem 16:2235–2260
5. Kelland LR (2000) Preclinical perspectives on platinum resistance. Drugs 59(Suppl 4):1–8 discussion 37-38
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献